New application of esterified derivative of p-hydroxycinnamic acid

Abstract

The invention relates to the technical field of biological medicines, in particular to novel application of p-hydroxycinnamic acid esterified derivatives. Research finds that an esterified derivative of p-hydroxycinnamic acid, especially methyl 4-valerylcinnamate, can effectively relieve inflammatory response of intestinal tracts and skin, protect colonic mucosal barriers and repair functional factors of intestinal barriers, so that symptoms of ulcerative colitis and atopic dermatitis are effectively relieved, the life quality of patients is improved, and the curative effect of the patients is improved. Good clinical application prospects and potential market values are realized.

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to novel uses of esterified derivatives of p-hydroxycinnamic acid. Background Technology

[0002] Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease that primarily affects the mucosal layer of the large intestine. Its exact cause is not fully understood, but it may be related to genetic, immune, environmental factors, and gut microbiota. Common symptoms include abdominal pain, diarrhea (often accompanied by bloody stools), weight loss, and fatigue. Severe cases can be life-threatening due to complications such as intestinal perforation and intestinal bleeding.

[0003] Currently, treatment for ulcerative colitis (UC) primarily includes drug therapy, nutritional therapy, and surgery. Commonly used drug therapies include aminosalicylic acid derivatives, steroids, and immunosuppressants. In addition, biologics (such as anti-TNF-α antibodies) are widely used in patients with moderate to severe ulcerative colitis, showing good efficacy. However, existing treatments have certain limitations, such as the potential side effects of long-term steroid use, and the insufficient response of some patients to immunosuppressants and biologics, resulting in a continued probability of relapse and refractory disease. Therefore, there is an urgent need to develop novel treatment methods to better control and improve patients' conditions.

[0004] Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by itching, dryness, redness, and skin lesions. It can begin in childhood and is often accompanied by other atopic disorders such as allergic rhinitis and asthma. The exact pathogenesis of atopic dermatitis is not fully understood, but it is closely related to genetic factors, immune system dysregulation, and external stimuli. This disease not only causes physical discomfort but also significantly impacts patients' mental health and quality of life.

[0005] For Alzheimer's disease (AD), treatment primarily involves controlling the condition with topical and systemic medications. However, long-term use of steroids can lead to adverse reactions such as skin atrophy, while immunosuppressants may significantly increase the risk of infection. Therefore, finding safer and more effective new treatment options is imperative.

[0006] KS-3 valerate is a novel synthetic compound synthesized by acylation of methyl p-hydroxycinnamate (KS-3) with valerate. Current research has confirmed that KS-3 can prevent or treat oligospermia and asthenospermia, but its therapeutic effects on ulcerative colitis and atopic dermatitis have not yet been found. Summary of the Invention

[0007] In view of this, the present invention provides a new application of esterified derivatives of p-hydroxycinnamic acid, specifically in the preparation of medicaments for the prevention and treatment of colitis and / or dermatitis.

[0008] Methyl p-hydroxycinnamate (KS-3) is an esterified derivative of 4-hydroxycinnamic acid. While its effects in preventing or treating oligospermia and asthenospermia have been reported, its therapeutic effects on colitis and dermatitis have not been disclosed. The applicant's research found that KS-3 itself has no significant therapeutic effect on colitis and dermatitis, but the esterified derivatives of methyl p-hydroxycinnamate obtained by esterification of the hydroxyl group and ester of methyl p-hydroxycinnamate have significant therapeutic effects. This invention has found that esterified derivatives obtained by esterification reactions of different acids (such as acetic acid, propionic acid, butyric acid, valeric acid, etc.) with the phenolic hydroxyl group of methyl p-hydroxycinnamate, as well as esterified derivatives generated by the reaction of the carboxyl group of p-hydroxycinnamic acid with different alcohols (such as methanol, propanol, butanol, pentanol, etc.), all have certain preventive and therapeutic effects on colitis and dermatitis. Among them, the valeric acid esterified derivative of methyl p-hydroxycinnamate, namely methyl 4-valeroyloxycinnamate, has the best preventive and therapeutic effect.

[0009] This invention provides the use of esterified derivatives of p-hydroxycinnamic acid in the preparation of medicaments for the prevention and treatment of colitis. In some embodiments, the colitis is ulcerative colitis.

[0010] This invention has found that the valerate derivative of KS-3 has the best therapeutic effect on ulcerative colitis, and its effect is significantly better than that of the esterified derivative of KS-3 and the esterified derivative of p-hydroxycinnamic acid.

[0011] This invention also provides the use of esterified derivatives of p-hydroxycinnamic acid in the preparation of medicaments for the prevention and treatment of dermatitis. In some embodiments, the dermatitis is atopic dermatitis.

[0012] In the above applications, the esterified derivative is selected from valerate derivatives or butyrate derivatives.

[0013] In some specific embodiments, the esterified derivative of p-hydroxycinnamic acid is selected from at least one of methyl 4-pentanoyloxycinnamate, methyl 4-acetoxycinnamate, methyl 4-propanoyloxycinnamate, methyl 4-butanoyloxycinnamate, methyl p-hydroxycinnamate, propyl 4-pentanoyloxycinnamate, butyl 4-pentanoyloxycinnamate, and pentanoyloxycinnamate.

[0014] The specific structure of the esterified derivative is as follows:

[0015] 4-Valanoyloxymethyl cinnamate, namely the valeric acid ester derivative of methyl p-hydroxycinnamate (KS-3) (KS-3 valerate), has the following structural formula:

[0016] .

[0017] The acetic acid esterification derivative of methyl p-hydroxycinnamate (KS-3), namely methyl 4-acetoxycinnamate (KS-3 acetate), has the following structural formula:

[0018] .

[0019] The propionyl ester derivative of methyl p-hydroxycinnamate (KS-3), namely methyl 4-propionyloxycinnamate (KS-3 propionate), has the following structural formula:

[0020]

[0021] The butyrate derivative of methyl p-hydroxycinnamate (KS-3), namely methyl 4-butyryloxycinnamate (KS-3 butyrate), has the following structural formula:

[0022] .

[0023] The methanol esterification derivative of p-hydroxycinnamic acid, namely methyl p-hydroxycinnamate (KS-3), has the following structural formula:

[0024]

[0025] The propanol esterification derivative of 4-pentanoyloxycinnamic acid, namely propyl 4-pentanoyloxycinnamic acid (COA-L5R3), has the following structural formula:

[0026]

[0027] The butanol esterified derivative of 4-pentanoyloxycinnamic acid, namely butyl 4-pentanoyloxycinnamic acid (COA-L5R4), has the following structural formula:

[0028]

[0029] The pentanol esterification derivative of 4-pentanoyloxycinnamic acid, namely pentanoyloxycinnamic acid pentyl ester (COA-L5R5), has the following structural formula:

[0030]

[0031] In the above applications, the prevention and treatment include: regulating the level of inflammatory factors, increasing the level of oxidative stress, and / or repairing intestinal barrier function factors.

[0032] Specifically, the inflammation-related factors include at least one of TNF-α, IL-6, IL-1β, IL-10, TSLP, IFN-γ, IL-4, and IL-33.

[0033] In a specific embodiment of the present invention, the regulation of inflammation-related factor levels includes: reducing the level of at least one inflammatory factor among TNF-α, IL-6, IL-1β, TSLP, IFN-γ, IL-4 and IL-33, and / or increasing the level of the anti-inflammatory factor IL-10.

[0034] Specifically, the indicators of oxidative stress include at least one of NRF2, NQO1, and HO-1.

[0035] Specifically, the intestinal barrier function factors include at least one of ZO-1, Occludin, MUC1, and MUC2.

[0036] This invention has found that KS-3 valerate has significant preventive and therapeutic effects on colitis and / or dermatitis in humans or animals. The animals include mice, rats, guinea pigs, rabbits, apes, monkeys, chimpanzees, cattle, sheep, pigs, horses, dogs, or cats.

[0037] This invention also provides a medicament for the prevention and treatment of colitis and / or dermatitis, comprising methyl 4-pentanoyloxycinnamate and pharmaceutically acceptable excipients. The pharmaceutically acceptable excipients include fillers, binders, disintegrants, lubricants, suspending agents, matrices, preservatives, flavoring agents, sweeteners, etc., prepared according to conventional pharmaceutical manufacturing methods to form pharmaceutically acceptable conventional dosage forms, including but not limited to granules, tablets, capsules, pellets, oral liquids, syrups, suspensions, lozenges, orally disintegrating tablets, ointments, pastes, patches, and sprays.

[0038] In some embodiments, the medicament described in this invention may also include other drugs for the prevention and treatment of colitis and / or dermatitis. These other drugs for the prevention and treatment of colitis and / or dermatitis may be commonly used Western or traditional Chinese medicines in the art. The Western medicines include, but are not limited to, 5-aminosalicylic acids (5-ASA), glucocorticoids (such as prednisone, hydrocortisone, etc.), immunosuppressants (such as azathioprine, 6-mercaptopurine, etc.), biologics (such as infliximab, adalimumab, etc.), and antibiotics (such as metronidazole, ciprofloxacin, etc.).

[0039] The present invention also provides a method for preventing and / or treating colitis, comprising: administering an esterified derivative of p-hydroxycinnamic acid (including an esterified derivative of p-hydroxycinnamic acid or an esterified derivative of methyl p-hydroxycinnamic acid, etc.) as described above.

[0040] In some implementations, the colitis is ulcerative colitis.

[0041] The present invention also provides a method for preventing and / or treating dermatitis, comprising: administering an esterified derivative of p-hydroxycinnamic acid (including an esterified derivative of p-hydroxycinnamic acid or an esterified derivative of methyl p-hydroxycinnamic acid, etc.) as described above.

[0042] In some implementations, the dermatitis is atopic dermatitis.

[0043] In the applications, drugs, and methods described above in this invention, the effective concentration of the esterified derivative of p-hydroxycinnamic acid is 7.5 mM to 30 mM. Specifically, the effective concentration can be 7.5 mM, 15 mM, 30 mM, or any value between any two values ​​or any small range.

[0044] The present invention has the following beneficial effects:

[0045] (1) KS-3 valerate has significant anti-inflammatory effects. Experimental results show that KS-3 valerate can inhibit the production of pro-inflammatory factors, such as TNF-α, IL-6, IL-4, and IL-33. This inhibitory effect can effectively reduce the inflammatory response in the intestines and skin, thereby alleviating the patient's symptoms and improving their quality of life. At the same time, reducing the production of inflammatory mediators can also reduce tissue damage caused by inflammation, thus providing more patients with treatment opportunities.

[0046] (2) KS-3 valerate exhibited significant antioxidant effects in both UC and AD mouse models, significantly increasing the mRNA expression levels of antioxidant-related genes, including NRF2, HO-1, and NQO1. The upregulation of NRF2, a key antioxidant transcription factor, promoted the synthesis of downstream antioxidant enzymes, thereby enhancing the cell's resistance to oxidative stress. Increased HO-1 and NQO1 also indicated enhanced cellular self-protection mechanisms, contributing to the relief of inflammation and repair of damaged tissues. These results suggest that KS-3 valerate, by enhancing the antioxidant defense system, not only alleviates the pathological manifestations of UC and AD but also provides a new treatment strategy for improving the overall health of patients. Therefore, it may offer a safer treatment option in clinical applications, especially suitable for long-term use.

[0047] (3) KS-3 valerate's ability to improve intestinal barrier function gives it a unique advantage in the treatment of UC and AD. UC is usually accompanied by damage to the intestinal barrier, leading to the invasion of pathogens and toxins, which in turn aggravates the inflammatory response. Research results show that KS-3 valerate can significantly increase the expression levels of key adhesion protein and mucin genes in the colon, including tight junction proteins ZO-1 and Occludin, as well as the mRNA expression of mucins MUC1 and MUC2. These proteins play a crucial role in maintaining the integrity and function of the intestinal barrier. KS-3 valerate effectively improves intestinal barrier function and reduces intestinal permeability by enhancing the tight junctions of intestinal epithelial cells and promoting mucus secretion. This mechanism can not only reduce the penetration of harmful substances into the intestine, but also promote intestinal health and reduce the risk of recurrence.

[0048] In summary, the KS-3 valerate of the present invention can effectively alleviate the symptoms of UC and AD and improve the quality of life of patients through its multiple mechanisms of action, and has good clinical application prospects and potential market value. Attached Figure Description

[0049] Figure 1 The effects of eight drugs on DSS-induced UC are shown below. A represents the change in body weight in each group after gavage administration of the drugs to BALB / c mice; B represents the DAI score; C represents colon images; D represents colon length; E represents the colonic ZO-1 mRNA expression level in each group; and F represents the Occludin mRNA expression level. * indicates p < 0.05; ** indicates p < 0.01.

[0050] Figure 2 The effect of different concentrations of KS-3 valerate on DSS-induced UC is shown in the figure. A represents the body weight curves of each group after gavage administration of the drug to BALB / c mice; B represents colon images; C represents colon length; D represents DAI score; * indicates p<0.05; ** indicates p<0.01.

[0051] Figure 3 To improve DSS-induced UC in BALB / c mice, A represents the body weight curves of each group after gavage administration; B represents colon images; C represents colon length; D represents DAI score; * indicates p<0.05; ** indicates p<0.01;

[0052] Figure 4 KS-3 valerate can reduce colonic inflammation in UC mice. In the figure, A represents the colonic TNF-α mRNA expression level in each group after gavage administration of the drug to BALB / c mice; B represents the IL-6 mRNA expression level; C represents the IL-1β mRNA expression level; D represents the IL-10 mRNA expression level; * indicates p<0.05; ** indicates p<0.01.

[0053] Figure 5 KS-3 valerate can reduce the level of oxidative stress in the colon of UC mice. In the figure, A represents the expression level of NRF2 mRNA in the colon of each group after gavage administration of the drug to BALB / c mice; B represents the expression level of NQO1 mRNA; C represents the expression level of HO-1 mRNA; * indicates p<0.05; ** indicates p<0.01.

[0054] Figure 6To protect the colonic mucosal barrier of UC mice with KS-3 valerate, where A represents the colonic ZO-1 mRNA expression level in each group after gavage administration of the drug to BALB / c mice; B represents the Occludin mRNA expression level; C represents the MUC1 mRNA expression level; D represents the MUC2 mRNA expression level; * indicates p<0.05; ** indicates p<0.01;

[0055] Figure 7 To improve MC903-induced AD with KS-3 valerate, A represents ear redness and swelling in each group after gavage; B represents colon images; C represents colon length; * indicates p<0.05; ** indicates p<0.01;

[0056] Figure 8 KS-3 valerate can reduce ear inflammation in AD mice. In the figure, A represents the TSLP mRNA expression level in the ear of each group after gavage administration of the drug to BALB / c mice; B represents the IFN-γ mRNA expression level; C represents the IL-4 mRNA expression level; D represents the IL-33 mRNA expression level; * indicates p<0.05; ** indicates p<0.01.

[0057] Figure 9 KS-3 valerate can reduce the level of oxidative stress in the ears of AD mice. In this study, A represents the expression level of NRF2 mRNA in the colon of each group after gavage administration of the drug to BALB / c mice; B represents the expression level of NQO1 mRNA; C represents the expression level of HO-1 mRNA; * indicates p<0.05; ** indicates p<0.01.

[0058] Figure 10 To protect the colonic mucosal barrier of AD mice with KS-3 valerate, where A represents the colonic ZO-1 mRNA expression level in each group after gavage administration of the drug to BALB / c mice; B represents the Occludin mRNA expression level; C represents the MUC1 mRNA expression level; D represents the MUC2 mRNA expression level; * indicates p<0.05; ** indicates p<0.01. Detailed Implementation

[0059] This invention provides novel applications for esterified derivatives of p-hydroxycinnamic acid. Those skilled in the art can refer to this document and appropriately modify the process parameters to achieve the desired results. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The methods and applications of this invention have been described through preferred embodiments; those skilled in the art will clearly be able to modify or appropriately alter and combine the methods and applications described herein without departing from the content, spirit, and scope of this invention to realize and apply the technology of this invention.

[0060] In this article, expressions such as “including,” “having,” and “containing,” as well as their grammatical synonyms, should be understood as open expressions that are inclusive rather than exclusive. The option of “composed of…” is also provided.

[0061] In addition to the publicly disclosed point values, the numerical ranges discussed in this article also cover all intermediate values ​​between any two endpoint values, including any numerical value between any two point values ​​and a small range within any two numerical ranges.

[0062] In this document, “one or more of…” individually includes each of the objects described following the statement, as well as various different combinations of two or more of the described objects, unless otherwise understood from the context and usage. The statement “and / or” combined with three or more described objects should be understood to have the same meaning, unless otherwise understood from the context.

[0063] Unless otherwise specified, the test materials used in this invention are all commercially available products that can be purchased on the market.

[0064] In the embodiments of the present invention, each compound can be purchased from the market or prepared according to methods known to those skilled in the art.

[0065] The present invention will be further illustrated below with reference to the embodiments:

[0066] Example 1

[0067] 1.1 The optimal drug KS-3 valerate was selected using the UC model.

[0068] First, after acclimatizing for one week in an independently ventilated cage system (IVC) with suitable light and temperature, all mice were randomly divided into a control group, a model group, and a drug intervention group, with six mice in each group. A ulcerative colitis (UC) model was established using sodium dextran sulfate (DSS) aqueous solution (purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd. or Yisheng Biotechnology Shanghai Co., Ltd.). Except for the control group, all other groups were fed drinking water containing 2.5% or 3% (w / v) DSS to induce UC for 7 consecutive days. For 7 consecutive days, the mice were administered drugs by gavage, including the following compounds: 5-aminosalicylic acid, KS-3 acetate, KS-3 propionate, KS-3 butyrate, KS-3 valerate, propyl 4-valerate-oxycinnamate, butyl 4-valerate-oxycinnamate, and pentyl 4-valerate-oxycinnamate. 5-Aminosalicylic acid was used as a positive control at a dose of 100 mg / kg, while the other compounds were administered at a concentration of 30 mM, 0.1 mL daily by gavage. The calculated dose of KS-3-valerate was 39 mg / kg. Mouse weight changes and treatment efficacy were monitored daily, and mice were sacrificed on day 8. After dissection, the colon was photographed and fixed in 4% paraformaldehyde.

[0069] This invention first used 2.5% DSS (purchased from Shanghai Biede Pharmaceutical Technology Co., Ltd.) drinking water to establish a BALB / c mouse model. Several compounds were selected as the drug intervention group and administered via gavage to the BALB / c mouse model. Changes in various indicators of the mice were observed and recorded. The optimal compound, KS-3 valerate, was selected, showing significantly better effects than other compounds. KS-3 propionate showed the second best effect. Figure 1 Then, BALB / c mice were induced to develop a BALB / c model using drinking water containing 3% DSS (purchased from Yisheng Biotechnology Shanghai Co., Ltd.), and subsequently given different concentrations of KS-3 valerate. The optimal concentration of 30 mM was determined. See [link to relevant documentation]. Figure 2 BALB / c mice modeled with 2.5% DSS (purchased from Yisheng Biotechnology Shanghai Co., Ltd.) were used as subjects to compare the effects of KS-3 and valeric acid alone. Detailed results can be found in [link to study]. Figure 3 .

[0070] 1.2 KS-3 valerate reduces colonic inflammatory response in UC mice

[0071] After euthanizing the mice, the colon length of each group was photographed and recorded. RNA was extracted from colon tissue, reverse transcribed into cDNA, and then detected by RT-qPCR. The levels of TNF-α, IL-6, IL-1β, and IL-10 in BALB / c mice were recorded. Detailed results can be found in [link to results]. Figure 4 .

[0072] Table 1. Relevant primer sequences

[0073]

[0074] 1.3 KS-3 valerate can reduce colonic oxidative stress levels in UC mice.

[0075] RNA was extracted from colon tissue, reverse transcribed into cDNA, and detected by RT-qPCR. The levels of NRF2, NQO1, and HO-1 in BALB / c were recorded. Detailed results can be found in [link to results]. Figure 5 .

[0076] Table 2 Relevant Primer Sequences

[0077]

[0078] 1.4 KS-3 valerate protects the colonic mucosal barrier in UC mice

[0079] RNA was extracted from colon tissue, reverse transcribed into cDNA, and then detected by RT-qPCR. The levels of ZO-1, Occludin, MUC1, and MUC2 in BALB / c were recorded. Detailed results can be found in [link to results]. Figure 6 .

[0080] Table 3 Relevant Primer Sequences

[0081]

[0082] The results showed that the KS-3 valerate group had the longest colon and the lowest DAI score, significantly better than other groups, making KS-3 valerate the optimal compound. Gavage administration of KS-3 valerate significantly improved DSS-induced UC in BALB / c mice, significantly reduced colonic inflammation and oxidative stress levels, decreased TNF-α, IL-6, and IL-1β levels, and increased IL-10, NRF2, NQO1, and HO-1 levels. Simultaneously, KS-3 valerate protected the colonic mucosal barrier in UC mice and repaired intestinal barrier function factors such as ZO-1, Occludin, MUC1, and MUC2; all these indicators were significantly better than other compounds. In conclusion, KS-3 valerate can effectively alleviate UC symptoms through multiple mechanisms.

[0083] Example 2

[0084] 2.1 KS-3 valerate improves MC903-induced AD

[0085] First, after acclimatizing for one week in an IVC with suitable light and temperature, all mice were randomly divided into a control group, a model group, and a drug intervention group, with six mice in each group. An atopic dermatitis model was established by applying calcipotriol (MC903) solution (purchased from MCE) to the mouse ears. The control group received ultrapure water, while the other groups received 20 μL of MC903 evenly applied to both ears of the mice once daily for 7 days. The mice were administered the drug by gavage for 7 consecutive days, and changes in the ear skin were recorded using a digital camera on days 1, 4, and 7. On day 8, the mice were euthanized, and their ears and colons were fixed in 4% paraformaldehyde.

[0086] Observe and record the changes in each BALB / c indicator. See detailed results below. Figure 7 .

[0087] 2.2 KS-3 valerate can reduce ear inflammation in AD mice

[0088] After euthanizing the mice, photographs of the ears of each group were taken, and RNA was extracted from ear tissue, reverse transcribed into cDNA, and then detected by RT-qPCR. The levels of TSLP, IFN-γ, IL-4, and IL-33 in BALB / c mice were recorded. Detailed results can be found in [link to results]. Figure 8 .

[0089] Table 4 Relevant Primer Sequences

[0090]

[0091] 2,3KS-3-valerate can reduce oxidative stress levels in the ears of AD mice.

[0092] RNA was extracted from ear tissue, reverse transcribed into cDNA, and detected by RT-qPCR. The levels of NRF2, NQO1, and HO-1 in BALB / c were recorded. Detailed results can be found in [link to results]. Figure 9 .

[0093] 2.4 KS-3 valerate protects the colonic mucosal barrier in AD mice

[0094] After euthanizing mice, RNA was extracted from colon tissue, reverse transcribed into cDNA, and then detected by RT-qPCR. The levels of ZO-1, Occludin, MUC1, and MUC2 were recorded. Detailed results can be found in [link to results]. Figure 10 .

[0095] The above results indicate that oral administration of KS-3 valerate can effectively reduce ear inflammation and oxidative stress levels in AD mice. Specifically, the KS-3 valerate group showed almost no ear redness or swelling, significantly better than the KS-3 group and other groups. The KS-3 valerate group also exhibited the longest colon, significantly better than other groups. Compared to other groups, KS-3 valerate significantly reduced the levels of TSLP, IFN-γ, IL-4, and IL-33 in MC903 mice, and significantly increased the levels of NRF2, NQO1, and HO-1. Simultaneously, KS-3 valerate significantly increased the levels of intestinal barrier function factors such as ZO-1, Occludin, MUC1, and MUC2 mRNA, demonstrating a significant protective effect on the colonic mucosal barrier in AD mice. In conclusion, KS-3 valerate can effectively alleviate AD symptoms through multiple mechanisms.

[0096] The above are merely preferred embodiments of the present invention. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. Use of an esterified derivative of p-hydroxycinnamic acid in the preparation of a medicament for preventing and / or treating colitis and / or dermatitis.

2. Use according to claim 1, characterized in that, The esterified derivative is selected from at least one of acetic acid esterified derivative, propionic acid esterified derivative, butyric acid esterified derivative, valeric acid esterified derivative.

3. Use according to claim 1 or 2, characterized in that, The esterified derivative of p-hydroxycinnamic acid is selected from at least one of 4-valeryloxy cinnamic acid methyl ester, 4-acetyloxy cinnamic acid methyl ester, 4-propionyloxy cinnamic acid methyl ester, 4-butyryloxy cinnamic acid methyl ester, p-hydroxycinnamic acid methyl ester, 4-valeryloxy cinnamic acid propyl ester, 4-valeryloxy cinnamic acid butyl ester, 4-valeryloxy cinnamic acid pentyl ester.

4. The use according to any one of claims 1 to 3, characterized in that, The prevention and treatment include regulating the level of inflammation-related factors, increasing the level of oxidative stress, and / or repairing intestinal barrier function factors.

5. Use according to claim 4, characterized in that, The inflammation-related factors include at least one of TNF-α, IL-6, IL-1β, IL-10, TSLP, IFN-γ, IL-4, and IL-33. The indicators of oxidative stress include at least one of NRF2, NQO1, and HO-1. The intestinal barrier function factors include at least one of ZO-1, Occludin, MUC1, and MUC2.

6. The use according to any one of claims 1 to 5, characterized in that, The colitis and / or dermatitis is colitis and / or dermatitis of a human or an animal. The animal includes a mouse, a rat, a guinea pig, a rabbit, an ape, a monkey, a chimpanzee, a cow, a sheep, a pig, a horse, a dog, or a cat.

7. Use according to claim 6, characterized in that, The colitis is ulcerative colitis; the dermatitis is atopic dermatitis.

8. A medicament for the prophylaxis and / or treatment of colitis and / or dermatitis, characterized in that, It includes 4-valeryloxy cinnamic acid methyl ester and a pharmaceutically acceptable excipient.

9. The medicament according to claim 8, characterized in that, It also includes other medicaments for preventing and / or treating colitis and / or dermatitis.

10. The medicament according to claim 9, characterized in that, Its dosage forms include granules, tablets, capsules, drop pills, oral liquids, syrups, suspensions, lozenges, oral disintegrating tablets, ointments, pastes, patches, or sprays.

Images